

=> d his

(FILE 'HOME' ENTERED AT 06:02:08 ON 05 OCT 2007)

FILE 'REGISTRY' ENTERED AT 06:02:31 ON 05 OCT 2007

L1 STRUCTURE UPLOADED
L2 878 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 06:02:55 ON 05 OCT 2007

L3 105 S L2

FILE 'STNGUIDE' ENTERED AT 06:03:02 ON 05 OCT 2007

FILE 'REGISTRY' ENTERED AT 06:03:30 ON 05 OCT 2007

L4 STRUCTURE UPLOADED
L5 26 S L4 SAM SUB=L2
L6 703 S L4 SSS FULL SUB=L2

FILE 'STNGUIDE' ENTERED AT 06:04:01 ON 05 OCT 2007


FILE 'REGISTRY' ENTERED AT 06:04:05 ON 05 OCT 2007
L7 175 S L2 NOT L6

FILE 'CAPLUS' ENTERED AT 06:04:40 ON 05 OCT 2007

L8 8 S L7
L9 1 S US2001-517010/APPS
L10 7 S L8 NOT L9

FILE 'REGISTRY' ENTERED AT 06:05:26 ON 05 OCT 2007

=> d l1
L1 HAS NO ANSWERS
L1 STR




G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> d l4
L4 HAS NO ANSWERS



L4

STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.



chain nodes :

19

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 20 21 22 23 24 25

chain bonds :

1-19 19-20

ring bonds :

1-2 1-7 2-3 2-8 3-4 3-11 4-5 5-6 6-7 6-12 7-15 8-9 9-10 10-11 12-13 13-14
14-15 20-21 20-25 21-22 22-23 23-24 24-25

exact/norm bonds :

1-2 1-7 1-19 2-3 2-8 3-4 3-11 4-5 5-6 6-7 6-12 7-15 8-9 9-10 10-11 12-13
13-14 14-15 19-20

normalized bonds :

20-21 20-25 21-22 22-23 23-24 24-25



isolated ring systems :

containing 1 :

G1:C,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 19:CLASS 20:Atom 21:Atom 22:Atom 23:Atom
24:Atom 25:Atom



chain nodes :

19

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 20 21 22 23 24 25

chain bonds :

1-19 19-20

ring bonds :

1-2 1-7 2-3 2-8 3-4 3-11 4-5 5-6 6-7 6-12 7-15 8-9 9-10 10-11 12-13 13-14
14-15 20-21 20-25 21-22 22-23 23-24 24-25

exact/norm bonds :

1-2 1-7 1-19 2-3 2-8 3-4 3-11 4-5 5-6 6-7 6-12 7-15 8-9 9-10 10-11 12-13
13-14 14-15 19-20

normalized bonds :

20-21 20-25 21-22 22-23 23-24 24-25

isolated ring systems :

containing 1 : 20 :

G1:C,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 19:CLASS 20:Atom 21:Atom 22:Atom 23:Atom
24:Atom 25:Atom

L9 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:515475 CAPLUS
 DN 141:71360



TI Preparation of derivatives of and analogs of dibenzosuberone for use in pharmaceutical compositions as steroid hormone nuclear receptor modulators
 IN Coghlan, Michael Joseph; Green, Jonathan Edward; Grese, Timothy Alan; Jadhav, Prabhakar Kondaji; Matthews, Donald Paul; Steinberg, Mitchell Irvin; Fales, Kevin Robert; Bell, Michael Gregory
 PA Eli Lilly and Company, USA
 SO PCT Int. Appl., 457 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004052847	A2	20040624	WO 2003-US16213	20030613
	WO 2004052847	A3	20040910		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2489276	A1	20040624	CA 2003-2489276	20030613
	AU 2003302220	A1	20040630	AU 2003-302220	20030613
	BR 2003012095	A	20050329	BR 2003-12095	20030613
	EP 1519915	A2	20050406	EP 2003-810038	20030613
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1665780	A	20050907	CN 2003-815098	20030613
	JP 2005539088	T	20051222	JP 2004-559025	20030613
	US 2006063759	A1	20060323	US 2004-517010	20041203 <--
	IN 2004KN01910	A	20070126	IN 2004-KN1910	20041213
	MX 2004PA12998	A	20050516	MX 2004-PA12998	20041217
	ZA 2004010293	A	20060222	ZA 2004-10293	20041221
	NO 2005000397	A	20050304	NO 2005-397	20050125
PRAI	US 2002-391992P	P	20020626		
	WO 2003-US16213	W	20030613		

OS MARPAT 141:71360
 GI



AB Dibenzosuberone derivs., such as I [X = CH2; R, R1 = H, OH, CN, halogen,

alkoxy, sulfonylamino, amino, etc.; R2 = aryl, heteroaryl; R3 = H, alkyl], and heterocyclic analogs thereof, such as I [X = O, S, NH, NMe, etc.], were prepared for therapeutic use in the treatment of pathol. disorders susceptible to steroid hormone nuclear receptor modulation. These compds. are claimed for use the treatment of disorders, such as Conn's Syndrome, primary and secondary hyperaldosteronism, increased sodium retention, increased magnesium and potassium excretion (diuresis), increased water retention, hypertension (isolated systolic and combined systolic/diastolic), arrhythmias, myocardial fibrosis, myocardial infarction, Bartter's Syndrome, disorders associated with excess catecholamine levels, diastolic and systolic. congestive heart failure (CHF), psychoses, cognitive disorders, memory disturbances, depression, bipolar disorder, anxiety disorders, personality disorders, breast cancer, peripheral vascular disease, diabetic nephropathy, cirrhosis with edema and ascites, esophageal varicies, Addison's Disease, muscle weakness, increased melan in pigmentation of the skin, weight loss, hypotension, hypoglycemia, Cushing's Syndrome, obesity, hypertension, glucose intolerance, hyperglycemia, diabetes mellitus, osteoporosis, polyuria, polydipsia, inflammation, rheumatoid arthritis, asthma, or chronic obstructive pulmonary disease,. Diastolic or systolic congestive heart failure, autoimmune disorders, tissue rejection associated with organ transplant, malignancies such as leukemias and lymphomas, acute adrenal insufficiency, congenital adrenal hyperplasia, rheumatic fever, polyarteritis nodosa, granulomatous polyarteritis, inhibition of myeloid cell lines, immune proliferation/apoptosis, HPA axis suppression and regulation, hypercortisolemia, modulation of the Th1/Th2 cytokine balance, chronic kidney disease, stroke and spinal cord injury, hypercalcemia, hyperglycemia, acute adrenal insufficiency, chronic primary adrenal insufficiency, secondary adrenal insufficiency, congenital adrenal hyperplasia, cerebral edema, thrombocytopenia, and Little's syndrome, systemic inflammation, inflammatory bowel disease, systemic lupus erythematosus, discoid lupus erythematosus, polyarthritis nodosa, Wegener's granulomatosis, giant cell arthritis, rheumatoid arthritis, osteoarthritis, hay fever, allergic rhinitis, contact dermatitis, atopic dermatitis, exfoliative dermatitis, urticaria, angioneurotic edema, chronic obstructive pulmonary disease, asthma, tendonitis,. Bursitis, Crohn's disease, ulcerative colitis, autoimmune chronic active hepatitis, hepatitis, cirrhosis, inflammatory scalp alopecia, panniculitis, psoriasis, inflamed cysts, pyoderma gangrenosum, pemphigus vulgaris, bullous pemphigoid, dermatomyositis, eosinophilic fasciitis, relapsing polychondritis, inflammatory vasculitis, sarcoidosis, Sweet's disease, type 1 reactive leprosy, capillary hemangiomas, lichen planus,, erythema nodosum, acne, hirsutism, toxic epidermal necrolysis, erythema multiform, cutaneous T-cell lymphoma, emphysema, Alzheimer's Disease, and multipie sclerosis. Thus, dibenzosuberone derivative II (R = NMe) was prepared with

48%

yield via reaction of the corresponding sulfonyl chloride II (R = Cl) with MeNH₂ in THF. The prepared dibenzosuberone derivs. and analogs were assayed for mineralocorticoid and glucocorticoid receptor binding.

>> d 110 tot bib abs hitarr

ANSWERER CAPLUS CAPLUS COPYRIGHT 2007 ACS on STN
2006120489 CAPLUS Full-Text

DN 144:184724
TI Compounds as modulators of steroid hormone nuclear receptors
IN Micheli, Pierre-Yves; Petrassi, H. Michael; Richmond, Wendy; Pei, Wei
PA IRM LLC, Bermuda
SO PCT Int. Appl., 135 pp.
CODEN: PIXD02

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI WO 2006015259 A2 20060209 WO 2005-US27086 20050728
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MZ, NA,
NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BP, BJ,
CP, CO, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, AL,
KG, RU, KZ, MD, RU, TJ, TM

AU 2005267798 A1 20060209 AU 2005-267798 20050728
CA 2574737 A1 20060209 CA 2005-2574737 20050728
EP 1778242 A2 20070502 EP 2005-776623 20050728
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
BA, HR, MK, YU


IN 2007DN00633 A 20040803 IN 2007-DN633 20070123
PRAI US 2004-592076P P 200404728
WO 2005-US27086 W 20050728
OS MARPAT 144:184724

AB The invention provides compds., pharmaceutical compns. comprising such compds. and methods of using such compds. to treat or prevent diseases or disorders associated with the activation of steroid hormone nuclear receptors.


IT 875437-10-0P 875437-11-5P 875437-12-0P
875437-13-1P 875437-14-2P 875437-15-3P
875437-16-4P 875437-17-5P 875437-18-6P
875437-19-7P 875437-20-0P 875437-02-2P

RL: PAC (Pharmacological activity); SPP (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(steroid hormone nuclear receptors modulators for disease therapy)
RN 875437-10-8 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]- (CA INDEX NAME)



RN 875437-11-9 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-8-fluoro- (CA INDEX NAME)




RN 875437-12-0 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-8-methyl- (CA INDEX NAME)




RN 875437-13-1 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(2)-[10,11-dihydro-2-(phenylmethoxy)-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 875437-17-5 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(1)-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)propyl]-8-methyl- (CA INDEX NAME)



RN 875437-18-6 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(E)-(10,11-dihydro-2-hydroxy-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-8-methyl- (CA INDEX NAME)

Double bond geometry as shown.




RN 875437-19-7 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 6-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]- (CA INDEX NAME)

Double bond geometry as shown.


RN 875437-16-4 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(E)-(10,11-dihydro-2-(phenylmethoxy)-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-8-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 875437-20-0 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-2,2-dimethyl- (CA INDEX NAME)



RN 875437-22-2 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(2-fluoro-8-methoxydiben[b,e]oxepin-11(6H)-ylidene)methyl]-2,2,8-trimethyl- (CA INDEX NAME)



U.S. ANSWERS 2007 CAPLUS COPYRIGHT 2007 ACS ON STN

AN 2005-638871 CAPLUS Full-text

DN 143:153374

TI Preparation of tricyclic steroid hormone nuclear receptor modulators
IN Gavardinas, Konstantinos; Green, Jonathan Edward; Jadhav, Prabhakar
Kondajji, Matthews, Donald P.

EBI Lilly and Company, USA

SU PCT Int. Appl. 93 pp.

CODEN: PIXXD2


DT Patent

LA English

860010-52-2P 860010-53-3P 860010-54-4P
860010-55-5P 860010-56-6P 860010-57-7P
860010-58-8P 860010-59-9P 860010-60-2P
860010-61-3P 860010-62-4P 860010-63-5P
860010-64-6P 860010-65-7P 860010-66-8PRL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzimidazolone-substituted tricyclic steroid hormone nuclear receptor modulators)

RN 710344-06-2 CAPLUS


CN 2H-Benzimidazol-2-one, 5-[(2,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-[(4-morpholinyl)propyl]- (CA INDEX NAME)



RN 860009-94-5 CAPLUS

CN 2H-Benzimidazol-2-one, 1-(1,1-dimethyl-2-(4-morpholinyl)ethyl)-5-[(E)-(3-fluorodiben[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 860009-95-6 CAPLUS

CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodiben[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(1-methyl-4-piperidinyl)- (CA INDEX NAME)


Double bond geometry as shown.

RN 860009-96-7 CAPLUS


CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodiben[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(1-methyl-4-piperidinyl)- (CA INDEX NAME)

PAN.CNT 1	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005066161	A1	20050721	WO 2004-0938233	20041208
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HK, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MX, MN, MM, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TU, TM, TN, TR, TT, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MM, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, PR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU	2004312293	A1	20050721	AU 2004-312293	20041208
CA	2549053	A1	20050721	CA 2004-2549053	20041208
EP	1697350	A1	20060906	EP 2004-811084	20041208
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
CN	1918151	A	20070221	CN 2004-80041853	20041208
BR	2004016882	A	20070227	BR 2004-16882	20041208
JP	2007515431	T	20070614	JP 2006-545655	20041208
US	2007037788	A1	20070215	US 2006-576761	20060421
IN	2006DN03757	A	20070622	IN 2006-DN757	20060421
NO	2006003329	A	20070914	NO 2006-3329	20060718
PRAI	US 2004-531283P	P	20031219		
MO	2004-0838233	W	20041208		
OS	MARPAT 143:153374				
GI					


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds, I (Y = CH₂, O; R₁ = H, F; R₃ = Z-heterocycl; Z = divalent alkyl; with some specific exceptions) are prepared. For instance, II is prepared from (E)-11-bromomethylene-3-fluoro-6,11-dihydrodibenzo[b,e]oxepine (preparation given) and 1-(1,1-dimethyl-2-(morpholin-4-yl)ethyl)-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1,3-dihydrobenzimidazol-2-one (preparation given) (dioxane, Na₂CO₃, [Ph₃P]4Pd, 90-100°, 5 days). II has Ki ≤ 500 nM for the mineralocorticoid receptor and Ki ≤ 1,000 nM for the glucocorticoid receptor. I are useful for the treatment of congestive heart disease, hypertension, rheumatoid arthritis or inflammation.IT 710344-06-2P 860009-94-5P 860009-95-6P
860009-96-7P 860009-97-8P 860009-98-9P
860009-99-0P 860010-00-0P 860010-01-1P
860010-02-2P 860010-03-3P 860010-04-4P
860010-05-5P 860010-06-6P 860010-07-7P
860010-08-8P 860010-09-9P 860010-10-2P
860010-11-3P 860010-12-4P 860010-13-5P
860010-14-6P 860010-15-7P 860010-16-8P
860010-17-9P 860010-19-1P 860010-21-5P
860010-23-7P 860010-25-9P 860010-26-0P
860010-27-1P 860010-28-2P 860010-29-3P
860010-30-6P 860010-32-5P 860010-34-0P
860010-36-2P 860010-38-4P 860010-40-6P
860010-42-0P 860010-44-2P 860010-45-3P
860010-46-4P 860010-48-6P 860010-50-0PRN 860009-96-7 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodiben[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(1-methyl-4-piperidinyl)- (CA INDEX NAME)

Double bond geometry as shown.


RN 860009-97-8 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodiben[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(1-methyl-4-piperidinyl)- (CA INDEX NAME)

Double bond geometry as shown.

RN 860009-98-9 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodiben[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(1-ethyl-3-pyrrolidinyl)-1,3-dihydro- (CA INDEX NAME)


Double bond geometry as shown.

Absolute stereochemistry.
Double bond geometry as shown.




RN 860009-99-0 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[2-(dimethylamino)ethyl]-5-[(E)-3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 860010-00-0 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 860010-01-1 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-


ylidene)methyl]-1,3-dihydro-1-(2-(4-methyl-1-piperazinyl)ethyl)- (CA INDEX NAME)

Double bond geometry as shown.



RN 860010-02-2 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(3S)-3-pyrrolidinyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



● HCl


RN 860010-03-3 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(1R)-1-methyl-2-(4-morpholinyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 860010-04-4 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(1S)-1-methyl-2-(4-morpholinyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 860010-05-5 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(4-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Double bond geometry as shown.



● HCl


RN 860010-06-6 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[2-((2S,6R)-2,6-dimethyl-4-morpholinyl)ethyl]-5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 860010-07-7 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(1-piperazinyl)ethyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 860010-08-8 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(3-pyrrolidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Double bond geometry as shown.



● HCl

RN 860010-09-9 CAPLUS
 CN 2H-Benzimidazol-2-one, 1-(3-azetidinyl)-5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 860010-10-2 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(2S)-2-pyrrolidinylmethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.

Absolute stereochemistry.

Double bond geometry as shown.

RN 860010-13-5 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 860010-14-6 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(1R)-1-methyl-2-(4-morpholinyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 860010-15-7 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(1S)-1-methyl-2-(4-morpholinyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



● HCl

RN 860010-11-3 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(2R)-2-pyrrolidinylmethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



Absolute stereochemistry.
 Double bond geometry as shown.



● HCl


RN 860010-12-4 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(4-methyl-1-piperazinyl)ethyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 860010-16-8 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1-[1,1-dimethyl-2-(4-morpholinyl)ethyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.




RN 860010-17-9 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1-[2-(2S,6R)-2,6-dimethyl-4-morpholinyl]-1,1-dimethylethyl-1,3-dihydro- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 860010-19-1 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 860010-21-5 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(1-piperazinyl)ethyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 860010-23-7 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(4-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Double bond geometry as shown.



● HCl


RN 860010-25-9 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(38)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 860010-26-0 CAPLUS
 CN 2H-Benzimidazol-2-one, 1-(3-azetidinyl)-5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)


Double bond geometry as shown.



● HCl

RN 860010-27-1 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(3R)-3-pyrrolidinyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



● HCl


RN 860010-28-2 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(38)-1-methyl-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 860010-29-3 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1-[(38)-1-ethyl-3-pyrrolidinyl]-1,3-dihydro- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 860010-30-6 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(4-methyl-1-piperazinyl)ethyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 860010-32-8 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 860010-34-0 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(4-piperidinyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 860010-35-2 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(3S)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RN 860010-38-4 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(1R)-1-methyl-2-(4-morpholinyl)ethyl- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 860010-44-2 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1-2-[(2S,6R)-2,6-dimethyl-4-morpholinyl]ethyl-1,3-dihydro- (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.




RN 860010-45-3 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(4-morpholinyl)propyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 860010-46-4 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(1-piperazinyl)propyl]- (CA INDEX NAME)

Double bond geometry as shown.





RN 860010-40-0 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(1S)-1-methyl-2-(4-morpholinyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 860010-42-0 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1-[(1,1-dimethyl-2-(4-morpholinyl)ethyl)-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.




RN 860010-48-6 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1-[(3S)-1-ethyl-3-pyrrolidinyl]-1,3-dihydro-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 860010-47-5
 CMF C28 H25 P2 N3 O2

Absolute stereochemistry.
 Double bond geometry as shown.



CM 2


CRN 64-19-7
 CMF C2 H4 O2



RN 860010-50-0 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(3S)-1-methyl-3-pyrrolidinyl]-, monoacetate (9CI) (CA INDEX NAME)

CM 1
 CRN 860010-49-7
 CMF C27 H23 P2 N3 O2

Absolute stereochemistry.
 Double bond geometry as shown.




CM 2
 CRN 64-19-7
 CMF C2 H4 O2



RN 860010-52-2 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1-[(3R)-1-ethyl-3-pyrrolidinyl]-1,3-dihydro-, monoacetate (9CI) (CA INDEX NAME)

CM 1
 CRN 860010-51-1
 CMF C28 H25 P2 N3 O2

Absolute stereochemistry.
 Double bond geometry as shown.




CM 2

CRN 64-19-7
 CMF C2 H4 O2




RN 860010-53-3 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1-[(3R)-1-methyl-3-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.




RN 860010-54-4 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(2,6-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-[(1-piperazinyl)propyl]- (CA INDEX NAME)




RN 860010-55-5 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(2,6-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-[(2-(1-pyrrolidinyl)ethyl)- (CA INDEX NAME)



RN 860010-56-6 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(2,6-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1-[2-(dimethylamino)ethyl]-1,3-dihydro- (CA INDEX NAME)




RN 860010-57-7 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(2,6-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-[2-(4-methyl-1-piperazinyl)ethyl)- (CA INDEX NAME)




RN 860010-58-8 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(2,6-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-[(3S)-1-methyl-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 860010-59-9 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(2,6-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1-[(3S)-1-ethyl-3-pyrrolidinyl]-1,3-dihydro- (CA INDEX NAME)

Absolute stereochemistry.




RN 860010-60-2 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1-(1-ethyl-4-piperidinyl)-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.




RN 860010-61-3 CAPLUS
 CN 2H-Benzimidazol-2-one, 1-(1-ethyl-4-piperidinyl)-5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.




RN 860010-62-4 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1-(1-ethyl-4-piperidinyl)-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.




RN 860010-63-5 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(2,8-difluoro-10,11-dihydro-5H-

dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1-(1-ethyl-4-piperidinyl)-1,3-dihydro- (CA INDEX NAME)



RN 860010-64-6 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(4-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



Double bond geometry as shown.



● HCl

RN 860010-65-7 CAPLUS
 CN 2H-Benzimidazol-2-one, 1-[(3R)-1-ethyl-3-pyrrolidinyl]-5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



AB The photoreceptor has a photosensitive layer containing a charge-generating agent, an arylamine I hole-transporting agent (Ar1-Ar3 = (substituted) aromatic ring, (substituted) heterocycle; R1-R2 = H, (substituted) alkyl, (substituted) alkoxy, halo; X = O, S, CH2CH2, CH:CH, :CR3R4; R3-R4 = H, (substituted) alkyl), a stilbenequinone II electron-transporting agent [R5-R12 = (substituted) alkyl, (substituted) aralkyl, (substituted) aryl, (substituted) alkoxy, NO2, cyano, halo], and a binder resin. The process cartridge and the electrophotog. apparatus contain the photoreceptor. The photoreceptor showed improved charging stability and high sensitivity.

IT 120259-83-8
 RL: DEV (Device component use); USES (Uses)
 (hole-transporting agent; electrophotog. photoreceptor containing arylamine derivative and stilbenequinone derivative with improved charging stability)


RN 120259-83-8 CAPLUS
 CN 1-Naphthalenamine, 4-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-N,N-bis(4-methylphenyl)- (9CI) (CA INDEX NAME)



ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
 RN 1997:715726 CAPLUS Full-text
 DN 128:55376
 TI Electrophotographic photoreceptor with improved charging stability and process cartridge and electrophotographic apparatus containing it
 IN Kikuchi, Norihiro; Maruyama, Akio
 PA Canon K. K., Japan
 SO Jpn. Kokai Tokkyo Koho, 23 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1
 PI JP 09281729 A 19971031 JP 1996-114403 19960412
 JP 3273543 B2 20020408
 PRAI JP 1996-114403 19960412
 GI

ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
 RN 1996:609662 CAPLUS Full-text
 DN 125:261165
 TI Electrophotographic photoreceptor
 IN Hashimoto, Mitsuru


10517010 37 of 41
 PA Matsushita Electric Ind Co Ltd, Japan
 SO Jpn. Kokai Tokkyo Koho, 74 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 PAN.CNT 1
 PATENT NO. KIND DATE APPLICATION NO. DATE
 PI JP 08179527 A 19960712 JP 1994-322853 19941226
 PRAI JP 1994-322853
 GI




I

AB The electrophotog. photoreceptor comprises on its elec. conductive substrate a photosensitive layer containing I (R1 = amino, alkyl, cycloalkyl, hydroxy, acyl, carboxyl and its ester, aromatic hydrocarbon group, halo, CN, NO2; R2 and R3 may be same or different; R4 = aromatic hydrocarbon group, aromatic heterocyclic group; R3 and R4 may form a ring; m = 0-7; n = 1, 2). This photoreceptor shows good durability and high sensitivity.
 IT 141930-6-8
 RL DEV (Device component use), USES (Uses)
 (electrophotog. photoreceptor from)
 RN 181930-69-8 CAPLUS
 CN 9,10-Anthracenedione, 2-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]- (9CI) (CA INDEX NAME)

10517010 38 of 41
 LA Japanese
 PAN.CNT 1
 PATENT NO. KIND DATE APPLICATION NO. DATE
 PI JP 07281462 A 19951027 JP 1994-93884 19940408
 PRAI JP 1994-93884
 GI




AB In the electrophotog. photoreceptor having a photosensitive layer on a conductive support, the photosensitive layer contains a styryl compound I (X = CH2CH₂Ar1CH₂; R1,2 = alkyl, aromatic, heterocyclic; R3,4 = H, halo, alkyl, alkoxy; Ar1 = aromatic, heterocyclic) and a triaryl compound Ar2Ar3Ar4 (Ar2,3,4 = Ph, in which 2 or 3 of Ph contains C2-4 alkyl) as a charge-transporting substance. The electrophotog. photoreceptor provided a charge-transporting layer free of crack and crack formation.
 IT 120259-83-8
 RL MOA (Modifier or additive use), TEM (Technical or engineered material use), USES (Uses)
 (charge-transporting substance in electrophotog. photoreceptor)
 RN 120259-83-8 CAPLUS
 CN 1-Naphthalenamine, 4-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-N,N-bis(4-methylphenyl)- (9CI) (CA INDEX NAME)



✓ ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
 1996:113269 CAPLUS Full-text
 DN 124:160306
 TI Electrophotographic photoreceptor and apparatus using the same
 IN Kanamaru, Tetsuo; Nakada, Koichi; Kikuchi, Norihiro
 PA Canon KK, Japan
 SO Jpn. Kokai Tokkyo Koho, 34 pp.
 CODEN: JKXXAF
 DT Patent


✓ ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
 1992:184238 CAPLUS Full-text

10517010 39 of 41
 DN 116:184238
 TI Organic electroluminescent device
 IN Ota, Masahumi; Onuma, Teruyuki; Kawamura, Pumio; Sakon, Hirota; Takahashi, Toshihiko
 PA Ricoh Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 9 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 PAN.CNT 1
 PATENT NO. KIND DATE APPLICATION NO. DATE
 PI JP 03200889 A 19910902 JP 1990-49796 19900228
 JP 2897138 B2 19900531
 US 5093210 A 19920303 US 1990-544905 19900628
 PRAI JP 1989-168826 A1 19890630
 JP 1989-168827 A1 19890630
 JP 1990-49796 A 19900228
 OS MARPAT 116:184238
 GI




10517010 40 of 41

✓ ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
 1989:202799 CAPLUS Full-text
 DN 110:202799
 TI Organic electrophotographic photoreceptor containing charge-transporting triaryleamine
 IN Goto, Satoshi; Sasaki, Osamu; Suzuki, Shinichi
 PA Konica Co., Japan
 SO Jpn. Kokai Tokkyo Koho, 11 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 PAN.CNT 1
 PATENT NO. KIND DATE APPLICATION NO. DATE
 PI JP 63235945 A 19880930 JP 1987-70569 19870324
 PRAI JP 1987-70569
 GI



AB The device, suited for use in large-area displays, comprises 21 organic compound layer sandwiched between a pair of electrodes, wherein 21 layer consists of R1R2Ar1(CH₂CH₂)nAr2 or I (R1-5 = (un)substituted alkyl, carbocyclic aromatic ring, heterocyclic aromatic ring; R1, R2 may form a ring; Ar1-5 = (un)substituted carbocyclic aromatic ring, heterocyclic aromatic ring; n = 1-3; X = C2H₄, CH₂CH₂, O, S, NR5).
 IT 140168-77-8
 RL: PRP (Properties)
 (hole-transporting layer from, for organic electroluminescent device)
 RN 140168-77-8 CAPLUS
 CN 1-Naphthalenamine, 4-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-N,N-diphenyl- (9CI) (CA INDEX NAME)



AB The title photoreceptor has a photosensitive layer containing a compound of the formula I (R1 = H, halo, alkyl, alkoxy; R2 = H, alkyl, aryl; R3, R4 = aryl; Z = phenylene, naphthylene; n = 0, 1, 2).
 IT 120259-83-8
 RL: USES (Uses)
 (electrophotog. charge-transporting substance)
 RN 120259-83-8 CAPLUS
 CN 1-Naphthalenamine, 4-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-N,N-bis(4-methylphenyl)- (9CI) (CA INDEX NAME)

